Camille L Bedrosian
CIK 1326969 · Chief Medical Officer · last filed 2026-09-14
Camille L Bedrosian is a Chief Medical Officer who has filed 53 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider sold $324.9K of AMLX on Sep 14, 2026. Across all open-market trades the lifetime net is −$6.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.0M across reported positions. 20 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RARE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 LEVERONI COURT
NOVATO, CA 94949
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AMLX | Chief Medical Officer | 278,064 | $27.09 | $7.53M | -$798.7K | 12 | 2026-09-14 |
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Director | 0 | $84.95 | $0 | $0 | 8 | 2026-09-01 |
| RYTM | Director | 7,000 | $89.47 | $626.3K | $0 | 8 | 2025-06-26 |
| RARE | EVP and Chief Medical Officer | 50,601 | $16.08 | $813.7K | -$6.04M | 19 | 2023-03-03 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | VP, Chief Medical Officer | — | $24.07 | — | $0 | 1 | 2007-04-18 |
Recent Filings
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-14 | AMLX | Sell (S) | −10,028 | -$324.9K | EDGAR |
| 2026-09-11 | AMLX | Notice (144) | −10,028 | -$324.9K | EDGAR |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Disp (D) | −22,225 | -$1.89M | EDGAR |
| 2026-08-20 | AMLX | Grant (A) | +22,807 | $0 | EDGAR |
| 2026-06-22 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Grant (A) | +5,925 | $0 | EDGAR |
| 2026-03-09 | AMLX | Grant (A) | +95,990 | $0 | EDGAR |
| 2026-03-04 | RYTM | Notice (144) | −64,540 | -$5.85M | EDGAR |
| 2026-03-04 | AMLX | Sell (S) | −6,461 | -$94.2K | EDGAR |
| 2026-03-03 | RYTM | Notice (144) | −35,460 | -$3.21M | EDGAR |
| 2026-03-02 | AMLX | Notice (144) | −6,461 | -$94.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.